Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.6, 2009-06, pp. : 507-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US

By Ivanova Jasmina I.

PharmacoEconomics, Vol. 27, Iss. 8, 2009-08 ,pp. : 681-691

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Analysis of Antidepressants for Major Depressive Disorder in the United Kingdom

By Freeman H.

PharmacoEconomics, Vol. 18, Iss. 2, 2000-08 ,pp. : 143-148

Adis International

Access to resources Recommend Favorite

Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data

By Wade Alan G.

PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. : 969-981

Adis International

Access to resources Recommend Favorite

Venlafaxine cost effective in major depressive disorder

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 574, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Influenza immunisation for US employees worth its cost

Inpharma, Vol. 1, Iss. 1299, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite